OCULAR THERAPEUTIX INC's ticker is OCUL and the CUSIP is 67576A100. A total of 153 filers reported holding OCULAR THERAPEUTIX INC in Q1 2021. The put-call ratio across all filers is 0.82 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $189,543 | -85.7% | 60,364 | -76.5% | 0.00% | – |
| Q2 2023 | $1,327,503 | +115.2% | 257,268 | +119.8% | 0.00% | – |
| Q1 2023 | $616,832 | +694.7% | 117,046 | +323.7% | 0.00% | – |
| Q4 2022 | $77,620 | -17.4% | 27,623 | +21.9% | 0.00% | – |
| Q3 2022 | $94,000 | -50.3% | 22,658 | -51.7% | 0.00% | – |
| Q2 2022 | $189,000 | -59.4% | 46,944 | -29.5% | 0.00% | – |
| Q4 2021 | $465,000 | -68.3% | 66,575 | -54.6% | 0.00% | – |
| Q3 2021 | $1,465,000 | -35.2% | 146,557 | -8.1% | 0.00% | – |
| Q2 2021 | $2,260,000 | +233.8% | 159,395 | +286.4% | 0.00% | – |
| Q1 2021 | $677,000 | -37.9% | 41,246 | -21.7% | 0.00% | – |
| Q4 2020 | $1,090,000 | +376.0% | 52,653 | +74.8% | 0.00% | – |
| Q3 2020 | $229,000 | -79.3% | 30,126 | -77.3% | 0.00% | -100.0% |
| Q2 2020 | $1,107,000 | +412.5% | 132,900 | +205.0% | 0.00% | – |
| Q1 2020 | $216,000 | +137.4% | 43,579 | +223.1% | 0.00% | – |
| Q2 2018 | $91,000 | – | 13,489 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SUMMER ROAD LLC | 6,122,089 | $19,223 | 100.00% |
| Opaleye Management Inc. | 6,468,000 | $20,309,520 | 6.61% |
| DELTEC ASSET MANAGEMENT LLC | 2,061,797 | $6,474,043 | 1.48% |
| Endurant Capital Management LP | 353,707 | $1,110,640 | 1.00% |
| SECTORAL ASSET MANAGEMENT INC | 969,350 | $3,043,759 | 0.59% |
| NOTTINGHAM ADVISORS, INC. | 194,266 | $609,995 | 0.09% |
| Covestor Ltd | 37,404 | $117 | 0.09% |
| GSA CAPITAL PARTNERS LLP | 233,582 | $733 | 0.06% |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | 342,111 | $1,074,229 | 0.03% |
| Polar Asset Management Partners Inc. | 263,763 | $828,216 | 0.02% |